Loomis, Sayles & Company
JAZZ icon

Loomis, Sayles & Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Loomis, Sayles & Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.9M Buy
205,905
+89,458
+77% +$15.6M 0.05% 129
2025
Q4 		$19.8M Sell
116,447
-11,540
-9% -$1.77M 0.02% 237
2025
Q3 		$16.9M Sell
127,987
-6,570
-5% -$788K 0.02% 263
2025
Q2 		$14.3M Sell
134,557
-9,111
-6% -$990K 0.02% 295
2025
Q1 		$17.8M Sell
143,668
-25,953
-15% -$3.39M 0.03% 258
2024
Q4 		$20.9M Buy
169,621
+62,969
+59% +$7.42M 0.03% 244
2024
Q3 		$11.9M Buy
106,652
+2,838
+3% +$311K 0.02% 334
2024
Q2 		$11.1M Buy
103,814
+13,152
+15% +$1.45M 0.02% 345
2024
Q1 		$10.9M Sell
90,662
-575
-0.6% -$70.4K 0.02% 345
2023
Q4 		$11.2M Sell
91,237
-3,262
-3% -$407K 0.02% 318
2023
Q3 		$12.2M Sell
94,499
-7,374
-7% -$983K 0.02% 303
2023
Q2 		$12.6M Buy
101,873
+3,051
+3% +$410K 0.02% 308
2023
Q1 		$14.5M Sell
98,822
-24,322
-20% -$3.6M 0.03% 276
2022
Q4 		$19.6M Sell
123,144
-6,733
-5% -$987K 0.04% 230
2022
Q3 		$17.3M Sell
129,877
-117,573
-48% -$17.9M 0.04% 231
2022
Q2 		$38.6M Sell
247,450
-19,709
-7% -$3.03M 0.07% 134
2022
Q1 		$41.6M Buy
267,159
+78,808
+42% +$11.4M 0.06% 161
2021
Q4 		$24M Buy
188,351
+6,119
+3% +$804K 0.03% 284
2021
Q3 		$23.7M Buy
182,232
+43,846
+32% +$6.62M 0.03% 278
2021
Q2 		$24.6M Buy
138,386
+10,265
+8% +$1.78M 0.03% 274
2021
Q1 		$21.1M Buy
128,121
+2,541
+2% +$418K 0.03% 277
2020
Q4 		$20.7M Sell
125,580
-3,888
-3% -$579K 0.03% 254
2020
Q3 		$18.5M Buy
129,468
+20,422
+19% +$2.53M 0.03% 245
2020
Q2 		$12M Buy
109,046
+17,730
+19% +$1.96M 0.02% 280
2020
Q1 		$9.11M Buy
91,316
+13,004
+17% +$1.68M 0.02% 292
2019
Q4 		$11.7M Sell
78,312
-4,527
-5% -$616K 0.02% 325
2019
Q3 		$10.6M Buy
82,839
+15,947
+24% +$2.14M 0.02% 337
2019
Q2 		$9.54M Buy
66,892
+6,643
+11% +$893K 0.02% 354
2019
Q1 		$8.61M Buy
+60,249
New +$7.86M 0.02% 373
2016
Q4 		– Sell
-35,949
Closed -$4.37M – 1065
2016
Q3 		$4.37M Sell
35,949
-460
-1% -$62K 0.01% 532
2016
Q2 		$5.14M Buy
36,409
+22,570
+163% +$3.33M 0.01% 515
2016
Q1 		$1.81M Buy
13,839
+50
+0.4% +$6.22K 0.01% 544
2015
Q4 		$1.94M Buy
13,789
+7,909
+135% +$1.1M 0.01% 557
2015
Q3 		$781K Buy
5,880
+785
+15% +$135K ﹤0.01% 573
2015
Q2 		$897K Sell
5,095
-226
-4% -$40.6K ﹤0.01% 575
2015
Q1 		$919K Buy
5,321
+4,753
+837% +$816K ﹤0.01% 601
2014
Q4 		$93K Sell
568
-4
-0.7% -$664 ﹤0.01% 673
2014
Q3 		$92K Hold
572
– – ﹤0.01% 659
2014
Q2 		$84K Buy
572
+133
+30% +$18.4K ﹤0.01% 702
2014
Q1 		$61K Sell
439
-31,639
-99% -$4.76M ﹤0.01% 701
2013
Q4 		$4.06M Sell
32,078
-11,377
-26% -$1.18M 0.01% 561
2013
Q3 		$4M Buy
43,455
+5,764
+15% +$465K 0.01% 552
2013
Q2 		$2.59K Buy
+37,691
New +$2.3M 0.01% 560

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Loomis, Sayles & Company's JAZZ Position: Q1 2026 in Review

Loomis, Sayles & Company increased its Jazz Pharmaceuticals (JAZZ) stake by 77% in Q1 2026, buying an estimated $15.6M and bringing the position to 205,905 shares worth $38.9M. The position accounts for 0.05% of the portfolio, ranked #129.

Loomis, Sayles & Company first reported a position in JAZZ in Q2 2013 and has held it in 43 quarters since. The position peaked at $41.6M in Q1 2022. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Loomis, Sayles & Company held 205,905 shares of Jazz Pharmaceuticals worth $38.9M as of Q1 2026.
  • Loomis, Sayles & Company bought 89,458 Jazz Pharmaceuticals shares in Q1 2026, an estimated $15.6M.
  • Jazz Pharmaceuticals made up 0.05% of Loomis, Sayles & Company's portfolio in Q1 2026, its #129 holding.
  • Loomis, Sayles & Company first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • Loomis, Sayles & Company's Jazz Pharmaceuticals position peaked at $41.6M in Q1 2022.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.